An Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of Lanreotide Autogel 90mg Every 4 Weeks in the Treatment of Symptomatic Polycystic Liver Disease, Including a Dose Escalation at Month 6 to Lanreotide Autogel 120mg for Non Responders
Latest Information Update: 28 Sep 2022
At a glance
- Drugs Lanreotide (Primary)
- Indications Polycystic liver disease
- Focus Therapeutic Use
- Acronyms LOCKCYST II
Most Recent Events
- 01 Apr 2014 New trial record